Your browser doesn't support javascript.
loading
Reply to the letter to the editor 'Re-aligning the ASCO and ESMO clinical benefit frameworks or modern cancer therapies'.
Cherny, N I; Dafni, U; Bogaerts, J; Latino, N J; Pentheroudakis, G; Douillard, J-Y; Tabernero, J; Zielinski, C; Piccart, M J; de Vries, E G E.
Afiliação
  • Cherny NI; Cancer Pain and Palliative Medicine Service, Department of Medical Oncology, Shaare Zedek Medical Center, Jerusalem, Israel. Electronic address: mcbs@esmo.org.
  • Dafni U; Laboratory of Biostatistics, School of Health Sciences, National and Kapodistrian University of Athens, Athens; Frontier Science Foundation-Hellas, Athens, Greece.
  • Bogaerts J; Methodology Direction, EORTC Headquarters, Brussels, Belgium.
  • Latino NJ; ESMO Head Office, Lugano, Switzerland.
  • Pentheroudakis G; Medical Oncology Department, Ioannina University Hospital, Ioannina, Greece.
  • Douillard JY; ESMO Head Office, Lugano, Switzerland.
  • Tabernero J; Medical Oncology Department, Vall d'Hebron University Hospital and Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, Barcelona, Spain.
  • Zielinski C; Division of Oncology, Medical University Vienna, Vienna, Austria.
  • Piccart MJ; Jules Bordet Institute, Universite Libre de Bruxelles, Brussels, Belgium.
  • de Vries EGE; Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Ann Oncol ; 29(3): 774-775, 2018 03 01.
Article em En | MEDLINE | ID: mdl-29161364
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Oncologia / Neoplasias Idioma: En Ano de publicação: 2018 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Oncologia / Neoplasias Idioma: En Ano de publicação: 2018 Tipo de documento: Article